<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9858">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688735</url>
  </required_header>
  <id_info>
    <org_study_id>IDEAS_PEDS_AD</org_study_id>
    <nct_id>NCT05688735</nct_id>
  </id_info>
  <brief_title>Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal</brief_title>
  <official_title>Prospective Randomized Vehicle-Controlled, Double-Blind Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrative Skin Science and Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sytheon Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Integrative Skin Science and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to compare coconut oil and sunflower seed oil derived isosorbide&#xD;
      disesters and colloidal oatmeal, and observe their effect on pediatric atopic dermatitis&#xD;
      among males and females aged 2-17.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2023</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind, randomized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Percent Achieving EASI 75</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Itch</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Change in the Itch Visual Analog Scale from Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>1 Week</time_frame>
    <description>Change in the EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Change in the EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Change in the EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch</measure>
    <time_frame>1 Week</time_frame>
    <description>Change in the Itch Visual Analog Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Change in the Itch Visual Analog Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topical steroid use</measure>
    <time_frame>1 Week</time_frame>
    <description>Cumulative use of topical steroid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topical steroid use</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Cumulative use of topical steroid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topical steroid use</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Cumulative use of topical steroid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Transepidermal Water Loss (TEWL)</measure>
    <time_frame>1 Week</time_frame>
    <description>TEWL measured with a Vapometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Transepidermal Water Loss (TEWL)</measure>
    <time_frame>4 Weeks</time_frame>
    <description>TEWL measured with a Vapometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Transepidermal Water Loss (TEWL)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>TEWL measured with a Vapometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Hydration</measure>
    <time_frame>1 week</time_frame>
    <description>Level of skin hydration measured SkinMoistureMeterSC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Hydration</measure>
    <time_frame>4 weeks</time_frame>
    <description>Level of skin hydration measured SkinMoistureMeterSC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Hydration</measure>
    <time_frame>8 weeks</time_frame>
    <description>Level of skin hydration measured SkinMoistureMeterSC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift in the Skin Microbiome</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in the relative abundance of Staphylococcus aureus on the skin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Experimental Topical Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical moisturizer With Colloidal Oatmeal and Isosorbide Diesters + Topical Steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Topical Product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical moisturizer With Colloidal Oatmeal WITHOUT Isosorbide Diesters + Topical Steroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isosorbide Diester Moisturizer</intervention_name>
    <description>Isosorbide Diesters (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5% ointment</description>
    <arm_group_label>Experimental Topical Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Moisturizer</intervention_name>
    <description>Topical vehicle (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5 % ointment</description>
    <arm_group_label>Control Topical Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ages 2-17 years old at the time of consent.&#xD;
&#xD;
          -  Clinical diagnosis of active atopic dermatitis&#xD;
&#xD;
          -  vIGA-AD (validated Investigator Global Assessment-Atopic Dermatitis) score of &quot;mild&quot;&#xD;
             (2) or &quot;moderate&quot; (3) at Baseline&#xD;
&#xD;
          -  EASI (Eczema Area and Severity Index) score of &gt;/= 5 at Baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who have a known allergy to isosorbide diesters, coconut oil, or sunflower&#xD;
             seed oil&#xD;
&#xD;
          -  Individuals who have solely hand and/or foot eczema without evidence of eczema&#xD;
             anywhere else on their body.&#xD;
&#xD;
          -  Individuals who have been on topical calcineurin inhibitors or crisaborole to the&#xD;
             predetermined areas within two weeks of initiation of participation or unwilling to&#xD;
             undergo a washout period.&#xD;
&#xD;
          -  Subjects with an ongoing secondary infection of the skin.&#xD;
&#xD;
          -  Subjects who are on systemic therapy or who need systemic therapy at the discretion of&#xD;
             the investigator. Systemic therapies include cyclosporine, systemic steroids,&#xD;
             methotrexate, and dupilumab. Subjects who have been on cyclosporine, systemic&#xD;
             steroids, or methotrexate in the month prior to initiation of study intervention or&#xD;
             are unwilling to undergo a washout period. Subjects who have been on dupilumab in two&#xD;
             months prior to initiation of study intervention or are unwilling to undergo a washout&#xD;
             period.&#xD;
&#xD;
          -  Subjects with a diagnosis of Scabies.&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raja Sivamani, MD</last_name>
    <phone>(916) 750-2463</phone>
    <email>raja.sivamani@integrativeskinresearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Integrative Skin Science and Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Dion</last_name>
      <phone>916-750-2463</phone>
      <email>caitlin@integrativeskinresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>April 12, 2023</last_update_submitted>
  <last_update_submitted_qc>April 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

